home / stock / vtyx / vtyx news

VTYX News and Press, Ventyx Biosciences Inc. From 08/16/22

Stock Information
Company Name: Ventyx Biosciences Inc.
Stock Symbol: VTYX
Market: NASDAQ
Website: ventyxbio.com
Menu
VTYX VTYX Quote VTYX Short VTYX News VTYX Articles VTYX Message Board
Get VTYX Alerts

News, Short Squeeze, Breakout and More Instantly...
VTYX - FUBO, CASI and KIRK among mid-day movers

Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...
VTYX - Artelo, Ventyx top healthcare gainers; Albireo, Sema4 lead losers' pack

Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...

VTYX - Ventyx Biosciences, Inc. (VTYX) CEO Raju Mohan on Q2 2022 Results - Earnings Call Transcript

Ventyx Biosciences, Inc. (VTYX) Q2 2022 Earnings Conference Call August 15, 2022 16:30 ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers C...

VTYX - Ventyx says lead asset well tolerated in a Phase 1 trial of healthy adults

Announcing initial data from a Phase 1 trial, the clinical-stage biopharma Ventyx Biosciences ( NASDAQ: VTYX ) said on Monday that its lead candidate VTX958 was well tolerated by 96 healthy adult volunteers who took part in the study. The two-part, randomized study consisted...
VTYX - Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Ventyx Biosciences press release ( NASDAQ: VTYX ): Q2 GAAP EPS of -$0.39 beats by $0.06 . VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable ...

VTYX - Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable securities of $258.4 million as of June 30, 2022, expected to support operations into the first half of 2024 ...

VTYX - Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

VTX958 was well-tolerated across all SAD and MAD cohorts with an excellent safety profile Class-leading target coverage, with TYK2 IC 50 and IC 90 coverage up to 24 hours Robust dose-dependent pharmacodynamic activity and evidence of target engage...
VTYX - Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need toda...

VTYX - SOS, XELA and MGNX among mid-day movers

Gainers: Qudian ( QD ) +48% . Marathon Digital ( MARA ) +32% . SQL Technologies ( SKYX ) +27% . SOS ( SOS ) +25% . Hut 8 Mining ( HUT ) +24% . North European Oil Royalty Trust ( NRT ) +24% . Advent Technologies ( ...

VTYX - Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals

VTX2735, a candidate from Ventyx Biosciences ( NASDAQ: VTYX ) for autoimmune and autoinflammatory conditions, met safety, tolerability, and pharmacokinetics goals in a phase 1 trial. The trial evaluated single ascending dose and multiple ascending doses. Drug-related ...
Previous 10 Next 10